DRugwatch BlogRSS 2.0

DRugwatch Blog > January 2012 > A New Era and Market Opportunity for Multaq

A New Era and Market Opportunity for Multaq

Matt KileenContributor: Matthew Killeen, Ph.D.


After a testing last year for Multaq (Sanofi’s dronedarone) – in 2011, its major PALLAS study was terminated and safety alerts were issued by the FDA and European Medicines Agency – 2012 offers a ray of hope for the antiarrhythmic drug. In January 2012, at the Boston Atrial Fibrillation Symposium, plans for a new clinical trial, testing a combination of Multaq and Ranexa (Gilead’s ranolazine) in AF patients were unveiled – a development strategy that Decision Resources had predicted over a year ago. Combination antiarrhythmic therapy for AF is a novel treatment approach that could deliver key benefits to patients, but developing such an agent poses a series of unique challenges. Given these factors, and the competitive landscape for antiarrhythmic drugs, what are the prospects for success of a Multaq and Ranexa combination therapy?


The HARMONY trial will investigate the effects of Multaq in combination with Ranexa in approximately 150 patients with non-permanent AF and implanted pacemakers – the enrollment of these patients will allow for investigators to quantify the therapy’s effects on AF burden. Although a small study, the results from HARMONY could lead to a paradigm shift in the treatment of AF.

Based on preclinical data, we believe that a Multaq and Ranolazine combination therapy could be well positioned to offer important benefits over current agents, which suffer from limited efficacy and/or safety concerns. Multaq and Ranexa have different modes of action and research in an animal model of AF showed that treatment with both agents yields synergistic antiarrhythmic effects. We expect that this finding prompted the choice of lower drug doses in the HARMONY trial (for example, only 150-225 mg of dronedarone will be tested vs. its current label of 400 mg twice daily). Additionally, Ranexa benefits from a strong safety profile; previous, intensive safety testing and Phase III research have shown that it poses no risk of major adverse events, particularly cardiac toxicity. Furthermore, although Multaq’s hepatic and cardiac safety profiles have been recently scrutinized, lower doses of the drug may reduce the risk of encountering these adverse events.

Despite the potential therapeutic benefits afforded by a Multaq and Ranexa combination therapy, it may face a number of regulatory and commercial challenges during its late-stage development and following its launch.  For example, given the risk of developing QT prolongation with both drugs, and Multaq’s prior history in the ANDROMEDA and PALLAS trials, the FDA is likely to demand a broad range of safety data in the form of dedicated studies (e.g., a thorough QT test) and at least one large outcomes-based trial. Selecting the optimal suite of safety studies and patient populations to enroll will prove crucial in demonstrating and reinforcing the combination’s safety to regulatory agencies and the medical community. The design of a subsequent Phase III program will also be pivotal in shaping physicians’ and payers’ perceptions of the combination’s efficacy and merits over existing agents; however, overcoming current perceptions of Multaq’s profile could prove challenging. Based on primary research conducted by Decision Resources, we believe that Multaq’s Phase III data from its ATHENA trial, which used an unconventional efficacy end point for AF (cardiovascular hospitalization), failed to resonate with prescribers and contributed to its modest uptake. Surveying cardiologists in the major markets to gauge the importance assigned to different efficacy end points in prescribing decisions could provide key insight into designing a Phase III study to fuel post launch uptake.

According to thought leaders interviewed by Decision Resources, the availability of safer and more effective antiarrhythmic drugs is a pressing unmet medical need in AF and, based on our current knowledge of the Multaq and Ranexa combination, we believe that it has the potential to offer important advantages over current agents. Nonetheless the combination therapy may face competition from key emerging drugs, such as oral vernakalant (Merck/Cardiome) and NTC-801 (Bristol-Myers Squibb/Teijin). The launch of Multaq, and the challenges it faced, provides the developers of new agents, including the combination therapy, with important learning opportunities regarding the design of late-stage AF trials, optimal end points to use, key patient subpopulations to target, and the best approaches to addressing regulators’ concerns. At this early stage in the combination’s development, harnessing this new insight to inform its future clinical pathway could play a major role in shaping its commercial success.
Posted on: 1/20/2012 2:12:09 PM | with 3 comments

Tags: Cardiovascular, Matt Killeen

Trackback URL: http://decisionresources.com/trackback/87c94813-93e1-4b91-badc-6ed124b06349/A-New-Era-and-Market-Opportunity-for-Multaq.aspx?culture=en-us

Matthew Killeen
Dear Joe,

Many thanks for your question.

As you rightly point out, amiodarone’s risk of extra-cardiac toxicity, such as lung and thyroid adverse events, is an important disadvantage for the drug. Nonetheless, it remains widely used for managing patients with non-permanent AF due to its powerful antiarrhythmic efficacy and ability to be used in patients with a broad range of comorbidities.

So far in the AF drug development field, matching amiodarone’s efficacy level has proven challenging; however, the Multaq and Ranexa combination therapy, by combining the different antiarrhythmic mechanisms of both agents, could come close to achieving similar, or even greater, efficacy than amiodarone. This would be a major advance in the field and address the overwhelming unmet need for safer and more effective antiarrhythmic drugs for AF.

The Multaq and Ranexa therapy is currently the only combination therapy that is being developed as an antiarrhythmic for AF. Additionally, many other promising early-stage antiarrhythmic agents are in early clinical development. In the coming years, we may well witness a sea change in AF treatment with new antiarrhythmic drugs, similar to current shifts in medical practice due to the new oral anticoagulants.

Best regards,

1/25/2012 4:36:44 PM

Joe Gregory
Also are there are other companies that have adopted a similar strategy for their products that fail early stage clinical trials?
1/24/2012 2:14:49 PM

Joe Gregory
Great article Dr. Killeen. Hopefully the therapeutic and safety benefits of this combined treatment regimen will be greater than those for the generic drug Amiodarone. The drug is extremely cheap but has been reported to have serious lung and thyroid consequences.
1/24/2012 12:36:18 PM

Leave comment Subscribe

What is the abbreviation for Accountable Care Organization?


rss twitter linkedin


DRugwatch Blog

Quick insight on intriguing drug market developments from Decision Resources’ analysts.

Recent posts

Post title:
Obesity drug approvals are like buses…
Post date:
3/27/2015 2:53:49 PM
Post Summary:

Contributors: Tim Blackstock
Topics: Obesity, Orexigen, Mysimba, Contrave, Saxenda, "Novo Nordisk", "Takeda Pharmaceutical", approvals

…there are none for ages and then several come along at once. In the United States, physicians managing obese patients were essentially only able to prescribe Roche’s Xenical (orlistat) and phentermine (and other noradrenergic anorectic agents) for years, and then Arena Pharmaceutical/Eisai’s Belviq (lorcaserin) and Vivus’s Qsymia (phentermine/topiramate fixed-dose combination [FDC]) were approved in June and July, respectively, during 2012.

Post title:
Sweet results for Contrave leave a bad taste in the mouth
Post date:
3/11/2015 11:26:21 AM
Post Summary:

Tim BlackstockContributor: Tim Blackstock
Topics: Obesity, Contrave, Mysimba, Orexigen, FDA, Regulatory Approval, Cardiovascular Outcomes

Orexigen has made interim data from the LIGHT study publically available in a financial report; details can be viewed here.

Post title:
Creating oral versions of injectable therapies for chronic diseases – a “win-win-win” concept
Post date:
3/6/2015 11:13:08 AM
Post Summary:

Stefanie MatlokContributor: Stefanie Hoffart
Therapeutic area: Cardiovascular and Metabolic Disorders

Novo Nordisk recently announced the first positive Phase 2 results for an oral GLP-1 analogue. Oral therapies are typically utilized in the early lines of therapy for type 2 diabetes, but as the disease progresses more aggressive treatment is required so patients can end up on multiple oral medications.

Post title:
Next Steps for Vorapaxar: EU PAD Label and Antidote Development?
Post date:
2/17/2015 10:49:37 AM
Post Summary:

Stefanie Matlok Graeme GreeneWriiten by: Stefanie Hoffart and Graeme Green

Topic: Cardiovascular

On January 19, 2015, the European Medicines Agency (EMA) approved the thrombin receptor antagonist vorapaxar (Merck’s Zontivity) for secondary prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI), co-administered with acetylsalicylic acid (ASA) and, if necessary, clopidogrel.

Post title:
Bococizumab: Late to Great? Dyslipidemia Déjà vu?
Post date:
2/12/2015 3:58:28 PM
Post Summary:
Tim BlackstockContributor: Tim Blackstock
Topics: Cardiovascular

The link between high low-density lipoprotein cholesterol (LDL-C) and cardiovascular (CV) risk is well established, as is, the evidence showing that agents that reduce LDL-C can prevent CV events.

Decision Resources Group brands include: